# A Phase 3 Clinical Study of KHK 4827

> **NCT02052609** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 155 (actual)

## Conditions studied

- Psoriasis Vulgaris
- Psoriatic Arthritis
- Pustular; Psoriasis, Palmaris Et Plantaris
- Psoriatic Erythroderma

## Interventions

- **DRUG:** KHK4827 140mg SC
- **DRUG:** KHK4827 210mg SC

## Key facts

- **NCT ID:** NCT02052609
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-01-28
- **Final completion:** 2016-07-04
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052609, "A Phase 3 Clinical Study of KHK 4827". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02052609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*